Clinical Trial Update: Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study comparing test and reference inhalation products in COPD patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: Lupin, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-04-05